Engineered microalgae and use in aquaculture

Engineered microalgae with dsRNA targeting Enterocytozoon hepatopenaei provide an effective and economical means to inhibit pathogenic infections in shrimp aquaculture, addressing the challenge of disease-related losses by using RNA interference to disrupt the pathogen's mechanisms.

WO2024238491A2PCT designated stage expired Publication Date: 2024-11-21REDUX BIO INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
PCT/US2024/029134
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Shrimp aquaculture faces significant economic losses due to diseases such as Enterocytozoon hepatopenaei, White Spot Syndrome Virus, and Yellow Head Virus, for which effective and economical prevention or treatment methods are lacking.

Method used

Engineered microalgae containing a double-stranded RNA (dsRNA) molecule that targets Enterocytozoon hepatopenaei, administered through feed additives or pellets, utilizing RNA interference to inhibit or treat pathogenic infections in crustaceans.

Benefits of technology

The engineered microalgae effectively inhibit or treat Enterocytozoon hepatopenaei infections by disrupting the pathogen's biological mechanisms, reducing infection severity and preventing its spread, offering a cost-effective solution for aquaculture.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000005_0001
    Figure IMGF000005_0001
Patent Text Reader

Abstract

The invention provides engineered microalgae comprising a double stranded RNA (dsRNA) that targets Enterocytozoon hepatopenaei, and methods of making and using the engineered microalgae in aquaculture.
Need to check novelty before this filing date? Find Prior Art

Description

ENGINEERED MICRO ALGAE AND USE IN AQUACULTURECROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims priority to U.S. provisional patent application 63 / 501,953 filed on May 12, 2023 the entire disclosure of which is hereby incorporated by reference.INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] Incorporated by reference in its entirety herein is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: One 75,174 Byte Extensible Markup Language (XML) file named "514841st26.xml," created on May 13, 2024.BACKGROUND OF THE INVENTION

[0003] Aquaculture of crustaceans (e.g., shrimp) plays an important role in meeting the worldwide demand for aquatic foods and foodstuffs. Roughly 55% of the global supply of food shrimp is farmed. Historically, shrimp aquaculture has been predominantly done in Asia, with China as the leading producer, and substantial industries in Indonesia, Thailand, India, and Vietnam. In recent years, shrimp aquaculture has expanded worldwide, particularly in the Americas, which, in 2021, collectively accounted for 30% of the global farmed shrimp output. Globally, in 2021, nearly 4,500,000 metric tons of shrimp were farmed, with production expected to surpass 5,000,000 metric tons in 2022.

[0004] Diseases that infect crustaceans pose a challenge for aquaculture. These diseases can cause slowed growth, stunting, and mortality among farm populations and, in some cases, can result in total loss of yield for an afflicted farm. Pathogens particularly problematic for shrimp farms include Enterocytozoon hepatopenaei (EHP), White Spot Syndrome Virus (“WSSV”), and Yellow Head Virus (“YHV”). In addition to their potential to devastate individual shrimp farms, the cumulative economic costs of pathogen-driven epidemics in aquaculture are extremely high. See, e.g., Patil al., Economic loss due to diseases in Indian shrimp farming with special referenceto Enter ocytozoon hepatopenaei (EHP) and white spot syndrome virus (WSS ), Aquaculture 533 (2021): 736231.

[0005] Various methods of treating crustaceans in aquaculture have been attempted, but there remains a need for effective and economical compositions and methods useful for the prevention or treatment of diseases.BRIEF SUMMARY OF THE INVENTION

[0006] Provided herein is an engineered microalgae comprising a heterologous dsRNA molecule that targets Enterocytozoon hepatopenaei, as well as compositions, such as feed additives and feed pellets, comprising the engineered microalgae, and methods of preparing same.

[0007] Further provided is a method of inhibiting a pathogenic Enterocytozoon hepatopenaei infection in a crustacean, the method comprising administering to the crustacean the engineered microalgae described herein or composition comprising same.

[0008] These and other aspects of the disclosure will be apparent from the following detailed description.DETAILED DESCRIPTION OF THE INVENTION

[0009] The present disclosure provides engineered microalgae comprising a double stranded RNA (dsRNA) that targets Enterocytozoon hepatopenaei (EHP), which infects crustaceans. The engineered microalgae containing the dsRNA can be administered to crustaceans in aquaculture, such as by feeding the microalgae to the crustaceans, whereby the dsRNA inhibits or treats the infection by way of RNA interference (RNAi).

[0010] Inhibiting the infection (or treating the infection) encompasses slowing or stopping the progress of the infection, or otherwise reducing the severity of the infection or any symptom thereof, in any manner and to any degree. Without wishing to be bound by any particular theory or mechanism of action, it is believed that the infection is inhibited or treated by disruption of the biological mechanisms that allow the pathogen to reproduce and / or spread in the host organism. The dsRNA can be administered as a treatment to infected crustaceans, or prophylactically to crustaceans showing no sign of infection, such that any subsequent infection will be inhibited ortreated. For convenience, the following discussion uses the terms “inhibiting” or “inhibit” with reference to a pathogenic infection as encompassing the “treatment” of a pathogenic infection.

[0011] EHP is a microsporidian parasite that infects the hepatopancreas of its host, causing hepatopancreatic microsporidiosis (HPM), a condition that has been associated with slow growth of the host in aquaculture settings. Thus, EHP infection is also sometimes referred to as hepatopancreatic microsporidiosis.

[0012] dsRNA that targets a given pathogen comprises a nucleotide sequence that hybridizes to at least a portion of the mRNA of a gene essential to infection or reproduction, thereby interfering with survival of the pathogen in the host. By hybridizing the mRNA, the dsRNA prevents translation of the mRNA, thereby inhibiting the infection, growth or survival of the pathogen. Without wishing by bound by any particular theory or mechanism of action, it is believed the dsRNA prevents translation by way of RNA interference (RNAi).

[0013] Accordingly, the dsRNA that targets EHP has a nucleic acid sequence that hybridizes to at least a portion of the mRNA of a gene essential to the parasite life cycle (e.g., infection or reproduction (including, e.g., spore forming and release) of EHP. In some embodiments, the dsRNA targets (e.g., comprises a nucleotide sequence that hybridizes to) a nucleic acid (e.g., mRNA) encoding an Enterocytozoon hepatopenaei spore wall protein, nucleoside transport protein, glucose-6-phosphate dehydrogenase, methionine aminopeptidase, polar tube protein, micorosomal signal peptidase, or hexokinase. In some embodiments, the dsRNA targets (e.g., comprises a nucleotide sequence that hybridizes to) a nucleic acid (e.g., mRNA) an Enterocytozoon hepatopenaei ATP / ADP transporter protein, optionally ATP-ADP Carrier Protein, ADP-ATP Carrier Protein, or ADP-ATP Carrier Protein 4. In some embodiments, the dsRNA targets (e.g., comprises a nucleotide sequence that hybridizes to) a nucleic acid (e.g., mRNA) encoding an Enterocytozoon hepatopenaei HXK, NTT-1, SWP, SWP-1, SWP-7, SWP- 12, ZWF1, MAP2, or SPCS1. In some embodiments, the dsRNA targets a polar tube protein (e g., EhPTP2). Additional information regarding some of the foregoing genes is provided in Table 1.Table 1*Gene ID from the MicrosporidiaDB (VEuPathDB Bioinformatics Resource Center, funded in part by the US National Institute of Allergy and Infectious Diseases and the Wellcome Trust; available online at «https: / / microsporidiadb.org / micro / app / » )

[0014] The dsRNA may be of any suitable length, and can be a hairpin construct (hairpin- dsRNA) or non-hairpin construct. The dsRNA typically have a length of 50 bp or more (e.g., 75bp or more, or 100 bp or more). In some instances even longer dsRNA are desired, such as 125 bp or more, 150 bp or more, or even 200 bp or more. In some embodiments, the dsRNA will have no more than 1000 bp, such as 750 bp or less, or 500 bp or less (e.g., 300 bp or less or 250 bp or less). Any of the foregoing lower and upper limits on dsRNA lengths can be set out as ranges (e.g., 50-1000 bp, 50-750 bp, 50-500 bp, 50-300 bp, 50-250, 75-1000 bp, 75-750 bp, 75- 500 bp, 75-300 bp, 75-250, 100-1000 bp, 100-750 bp, 100-500 bp, 100-300 bp, 100-250, 1250- 1000 bp, 125-750 bp, 125-500 bp, 125-300 bp, 125-250, 150-1000 bp, 150-750 bp, 150-500 bp, 150-300 bp, 150-250 200-1000 bp, 200-750 bp, 200-500 bp, 200-300 bp, 200-250, etc.). In some embodiments, the dsRNA has a length of 100-500 bp (e.g. 100-400 bp, 100-300 bp, or 100-250 bp), or 150-500 bp (e.g., 150-400 bp, 150-300 bp, or 150-250 bp). The foregoing dsRNA lengths refer to the double stranded portion of the dsRNA molecule (e.g., the portion of the dsRNA that hybridizes to a target mRNA, not including any hairpin loop region that might be present).

[0015] The dsRNA can, therefore, target (e.g., hybridize) to a region of the mRNA of a gene essential for the pathogen life cycle (e.g., a gene sequence of Table 1) having the above-stated length. In some embodiments, the dsRNA comprises a sequence identical to a region of the gene essential to the pathogen life cycle (e.g., a gene sequence of Table 1). In some embodiments, the dsRNA comprises a sequence identical to a 100-500 bp region (e.g. 100-400 bp, 100-300 bp, or 100-250 bp), or 150-500 bp (e.g., 150-400 bp, 150-300 bp, or 150-250 bp region) of a gene sequence set forth in Table 1. In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of SWP (e.g., SEQ ID NO: 15). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of of SWP12 (e g., SEQ ID NO: 16 or 17). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of ATP-ADP Carrier Protein (e.g., SEQ ID NO: 18). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of ADP-ATP Carrier Protein 4 (e.g., SEQ ID NO: 19 or 21). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) ofNTTl (e.g., SEQ ID NO: 20). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bpregion (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) ofZWFl Carrier Protein 4 (e.g., SEQ ID NO: 22). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of MAP2 (e.g., SEQ ID NO: 23). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100- 300 bp, 275-375 bp, or about 290-310 bp) of EhPTP2 (e.g., SEQ ID NO: 24). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of SPCS1 (e.g., SEQ ID NO: 25). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of HXK (e.g., SEQ ID NO: 26). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of SWP1 (e.g., SEQ ID NO: 27). In some embodiments, the dsRNA comprises a sequence identical to a 100-400 bp region (e.g. 100-300 bp, 275-375 bp, or about 290-310 bp) of SWP7 (e g., SEQ ID NO: 28).

[0016] Examples of dsRNA hairpin constructs targeting mRNA transcripts of some of the above genes are provided by SEQ ID NOs: 29-42. In some embodiments, the dsRNA comprises SEQ ID NO: 29, 30, or 31, targeting HXK. In some embodiments, the dsRNA comprises SEQ ID NO: 32, 33, or 34, targeting NTT 1. In some embodiments, the dsRNA comprises SEQ ID NO: 35 or 36 targeting SWP1. In some embodiments, the dsRNA comprises SEQ ID NO: 37 or 38 targeting SWP7. In some embodiments, the dsRNA comprises SEQ ID NO: 39, 40, 41, or 42 targeting EhPTP2. These dsRNA hairpin constructs include a dsRNA region comprising one strand complementary to a region of the target gene, a second strand complementary to the first strand, and a loop sequence connecting the two strands. It is understood that alternative embodiments of a dsRNA provided herein can comprise any of SEQ ID NOs: 29-41 without the loop sequence. For instance, a dsRNA targeting EhPTP2 can comprise a first nucleotide strand comprising the sequence of nucleotides 100-400 of SEQ ID NO: 24 and a second nucleotide strand complementary to the first strand; or a first nucleotide strand comprising the sequence of nucleotides 300-600 or 319-783 of SEQ ID NO: 24 and a second nucleotide strand complementary to the first strand; or a first nucleotide strand comprising the sequence of nucleotides 400-700 or 401-700 of SEQ ID NO: 24 and a second nucleotide strand complementary to the first strand; or a first nucleotide strand comprising the sequence ofnucleotides 556-855 of SEQ ID NO: 24 and a second nucleotide strand complementary to the first strand; or a first nucleotide strand comprising the sequence of nucleotides 650-855 of SEQ ID NO: 24 and a second nucleotide strand complementary to the first strand. For instance, the dsRNA can comprise a first nucleotide strand comprising any of SEQ ID NOs: 43-46 and a second nucleotide strand complementary thereto. Any of the foregoing can further comprise a linker or “loop” sequence (non-self hybridizing sequence) connecting the first and second strands.

[0017] The microalgae can be any type of microalgae that can be digested by crustaceans. In certain embodiments, the microalgae used with the methods of the invention are members of one of the following divisions: Chlorophyla, Cyanophyta (Cyanobacteria), or Heterokontophyta. In certain embodiments, the microalgae are members of one of the following classes:Chlor ophyceae, Bad liar iophy ceae, Eustigmatophyceae , Trebouxioficeae, and Chrysophyceae . In certain embodiments, the microalgae used with the methods of the invention are members of one of the following genera: Chlamydomonas, Nannochloropsis, Chlorella, Dunaliella, Scenedesmus, Selenastrum, Oscillatoria, Phormidium, Spirulina, Amphora, or Ochromonas. Further, non-limiting examples of microalgae species include for example, Achnanthes orientalis, Agmenellum spp., Amphiprora hyaline, Amphora coffeiformis, Amphora coffeiformis var. linea, Amphora coffeiformis var. punctata, Amphora coffeiformis var. taylori, Amphora coffeiformis var. tenuis, Amphora delicatissima, Amphora delicatissima var. capitata, Amphora sp., Anabaena, Ankistrodesmus, Ankistrodesmus falcatus, Boekelovia hooglandii, Borodinella sp., Botryococcus braunii, Botryococcus sudeticus, Bracteococcus minor, Bracteococcus medionucleatus, Carteria, Chaetoceros gracilis, Chaetoceros muelleri, Chaetoceros muelleri var. subsalsum, Chaetoceros sp., Chlamydomas perigranulata, Chlor e Ila anitrata, Chlorella antarctica, Chlorella aureoviridis, Chlorella Candida, Chlorella capsulate, Chlorella desiccate, Chlorella ellipsoidea, Chlorella emersonii, Chlorella fusca, Chlorella fusca var. vacuolata, Chlorella glucotropha, Chlorella infusionum, Chlorella infusionum var. actophila, Chlorella infusionum var. auxenophila, Chlorella kessleri, Chlorella lobophora, Chlorella hiteoviridis, Chlorella hiteoviridis var. aureoviridis, Chlorella hiteoviridis var. lutescens, Chlorella miniata, Chlorella minutissima, Chlorella mutabilis, Chlorella nocturna, Chlorella ovalis, Chlorella parva, Chlorella photophila, Chlorella pringsheimii , Chlorella protothecoides, Chlorellaprotothecoides var. acidicola, Chlorella regularis, Chlorella regularis var. minima, Chlorella regularis var. umbricata, Chlorella reisiglii, Chlorella saccharophila, Chlorella saccharophila var. ellipsoidea, Chlorella salina, Chlorella simplex, Chlorella sorokiniana, Chlorella sp., Chlorella sphaerica, Chlorella stigmatophora, Chlorella vanniellii, Chlorella vulgaris, Chlorella vulgaris fo. tertia, Chlorella vulgaris var. autotrophica, Chlorella vulgaris var. viridis, Chlorella vulgaris var. vulgaris, Chlorella vulgaris var. vulgaris fo. tertia, Chlorella vulgaris var. vulgaris fo. viridis, Chlorella xanthella, Chlorella zofingiensis, Chlorella trebouxioides, Chlorella vulgaris, Chlorococcum infusionum, Chlorococcum sp., Chlorogonium, Chroomonas sp., Chrysosphaera sp., Cricosphaera sp., Crypthecodinium cohnii, Cryptomonas sp., Cyclotella cryptica, Cyclotella meneghiniana, Cyclotella sp., Chlamydomonas moewusii Chlamydomonas reinhardtii Chlamydomonas sp. Dunaliella sp., Dunaliella bardawil, Dunaliella bioculata, Dunaliella granulate, Dunaliella maritime, Dunaliella minuta, Dunaliella parva, Dunaliella peircei, Dunaliella primolecta, Dunaliella salina, Dunaliella terricola, Dunaliella tertiolecta, Dunaliella viridis, Dunaliella tertiolecta, Eremosphaera viridis, Eremosphaera sp., Ellipsoidon sp., Euglena spp., Franceia sp., Fragilaria crotonensis, Fragilaria sp., Gleocapsa sp., Gloeothamnion sp., Haematococcus pluvialis, Hymenomonas sp., Isochrysis off. galbana, Isochrysis galbana, Lepocinclis, Micractinium, Micractinium, Monoraphidium minutum, Monoraphidium sp., Nannochloris sp., Nannochloropsis sp., Nannochlor opsis oculata, Nannochloropsis salina, Nannochloropsis gaditana, Navicula acceptata, Navicula biskanterae, Navicula pseudotenelloides, Navicula pelliculosa, Navicula sapr ophila, Navicula sp., Nephrochloris sp., Nephroselmis sp., Neochloris oleoabundans, Nitschia communis, Nitzschia alexandrina, Nitzschia closterium, Nitzschia communis, Nitzschia dissipata, Nitzschia frustuhim, Nitzschia hantzschiana, Nitzschia inconspicua, Nitzschia intermedia, Nitzschia microcephala, Nitzschia pusilia, Nitzschia pusilia elliptica, Nitzschia pusilia monoensis, Nitzschia quadrangular, Nitzschia sp., Ochromonas sp., Oocystis parva, Oocystis pusilia, Oocystis sp., Oscillator ia limnetica, Oscillator ia sp., Oscillatoria subbrevis, Parachlorella rotothecoides, Parachlor ell a kessleri, Pascheria acidophila, Pavlova sp., Phaeodactylum tricornutum, Phagus, Phormidium, Platymonas sp., Pleurochrysis carterae, Pleurochrysis dentate, Pleurochrysis sp., Prototheca wickerhamii, Prototheca stagnora, Prototheca portoricensis, Proto theca mor if or mis, Prototheca zopfii, Pseudochlorella aquatica, Pyramimonas sp., Pyrobotrys, Rhodococcusopacus, Sarcinoid chrysophyte, Scenedesmus armatus, Schizochytrium, Spirogyra, Spirulina platensis, Stichococcus sp., Synechococcus sp., Synechocystisf, Tagetes erecta, Tagetes patula, Tetraedron, Tetraselmis sp., Tetraselmis suecica, Tetraselmis chuii, Thalassiosiraweissflogii, and Viridiella fridericiana.

[0018] In some embodiments, the microalgae are Chlamyd.omas per igramilata, Chlamydomonas moewusii, Chlamydomonas reinhardlii, or CMamydomonas sp. In some embodiments, the microalgae are Phaeodactylum tricornutum.

[0019] In some embodiments, the microalgae is Prototheca microalgae. Most photosynthetic (or “green”) algae / microalgae form their cellular carbon exclusively through photosynthesis, and commercial production must be done in large ponds or photobioreactors. In contrast, Prototheca are non-photosynthetic (achlorophyllous) and can be grown via heterotrophic or “dark” fermentation in large-scale “dark” bioreactors using organic substrates as food. Without wishing to be bound by any particular theory or mechanism of action, it is believed that heterotrophic or “dark” fermentation of engineered Prototheca enables the production of microalgae compositions with greater cell density and higher concentration or total amount of desired therapeutic dsRNA more economically than alternative methods. This, in turn, allows for the cost-effective administration of the microalgae and any included therapeutic dsRNA in sufficient quantities to provide significant therapeutic value in aquaculture. In addition, it is believed that the cell walls of Prototheca are sufficiently robust to protect the dsRNA through processing, drying, storage and incorporation into feed, while still being readily digestible by the crustacean being treated. The Prototheca microalgae can be any species of Prototheca. In some embodiments, the Prototheca is a non-pathogenic species of Prototheca, optionally Prototheca moriformis or Prototheca zopfii (GT1).

[0020] In some embodiments, the engineered microalgae comprises dsRNA that targets Enterocytozoon hepatopenaei and further comprises other dsRNA targeting other pathogens (e g., parasites or viruses). For instance, the engineered microalgae can comprise multiple different dsRNA targeting Enterocytozoon hepatopenaei and one or more of White Spot Syndrome Virus (WSSV), Yellow Head Virus (YHV), Infectious Hypodermal and Hematopoietic Necrosis Virus (IHHNV), Decapod Iridescent Virus (DIV1), also known as Shrimp Hemocyte Iridescent Virus (SHIV), or Infectious Myonecrosis Virus (IMNV).Alternatively, the engineered microalgae can be part of a composition comprising two or more different engineered microalgae strains, wherein each strain comprises dsRNA that targets a different pathogen. Thus, for instance, such a composition can comprise microalgae comprising dsRNA that targets Enterocytozoon hepatopenaei and one or more additional microalgae (of the same or different type) comprising dsRNA targeting one or more of WSSV, YHV, IHHNV, DIV1 (or SHIV), or IMNV.

[0021] In some embodiments, the engineered microalgae comprises dsRNA that targets White Spot Syndrome Vims (WSSV). WSSV is a double-stranded DNA (“dsDNA”), rodshaped, enveloped vims that can infect a wide range of aquatic cmstaceans. The resulting disease is referred to as “White Spot Syndrome” presents with lethargy, reduced motility and appetite, and white spots in the exoskeleton, with hosts generally dying within 3-10 days. The WSSV genome encodes at least 35 different envelope proteins, with some isolates having more than 50 stmctural proteins. Viral proteins VP28, VP24, VP 19 and VP26, are the primary envelope proteins. Other essential proteins include ribonucleotide reductase subunits 1 and 2 (RR1 and RR2). In some embodiments, the dsRNA comprises a nucleotide sequence that hybridizes to a nucleic acid (e.g., mRNA) encoding a WSSV protein, and inhibits viral infection, replication, or both. For instance, the dsRNA can comprise a nucleotide sequence that hybridizes to a nucleic acid encoding a WSSV coat protein, such as VP28, VP26, VP24, or VP 19. In other embodiments, the dsRNA comprises a nucleotide sequence that hybridizes to a nucleic acid encoding VP37 or VP466. In still other embodiments, the dsRNA comprises a nucleotide sequence that hybridizes to a nucleic acid encoding an RR1 or RR2 gene of WSSV.

[0022] In some embodiments, the engineered microalgae comprises dsRNA that targets Yellow Head Vims (YHV). YHV is a shrimp pathogen that causes yellow head disease in infected hosts. YHV infects black tiger shrimp (Penaeus monodori), which comprises a substantial portion of the global shrimp aquaculture population. YHV is a rod-shaped, enveloped (+) single-stranded RNA (ssRNA) vims with a helical nucleocapsid. Infected shrimp exhibit decreased feeding activity and can show a bleached or yellowed overall appearance. YHV is a highly vimlent pathogen capable of horizontal transmission among shrimp, and can cause 100% mortality within a few days of the first signs of disease in an aquaculture population. The genome of YHV contains four open reading frames (ORFs) which code for non-stmcturalprotease proteins (ppi a and pplab), a nucleocapsid protein (p20), two envelope glycoproteins (gp64 and gpl 16), and a nonstructural triple membrane-spanning protein (p22). In some embodiments, the dsRNA comprises a nucleotide sequence that hybridizes to a nucleic acid (e.g., mRNA) encoding a YHV protein and inhibits viral infection, replication, or both. For instance, the dsRNA can comprise a nucleotide sequence that hybridizes to a nucleic acid encoding an envelope glycoprotein (e.g., gp64 or gpl 16), protease (ppla or pplab), or p22 of YHV.

[0023] In some embodiments, the engineered microalgae comprises dsRNA that targets Infectious Hypodermal and Hematopoietic Necrosis Virus (IHHNV). IHHNV is a singlestranded DNA-containing virus belonging to the family Parvoviridae . The IHHNV genome has three open reading frames (ORF1, ORF2, and ORF3) encoding non- structural proteins and the capsid protein. In some embodiments, the dsRNA targets ORF1. In some embodiments, the dsRNA targets ORF2. In some embodiments, the dsRNA targets ORF3.

[0024] In some embodiments, the engineered microalgae comprises dsRNA that targets Decapod Iridescent Virus (DIV1), also known as Shrimp Hemocyte Iridescent Virus (SHIV). The SHIV genome is publicly available (GenBank Accession MF599468).

[0025] In some embodiments, the engineered microalgae comprises dsRNA that targets, Infectious Myonecrosis Virus (IMNV). The IMNV genome comprises two open reading frames (ORFs). ORF1 encodes the major capsid protein (MCP), and its N-terminal region encodes a dsRNA- binding motif and two ‘2A-like’ cleavage motifs. ORF2 encodes an RNA-dependent RNA polymerase. In some embodiments, the dsRNA targets ORFl. In some embodiments, the dsRNA targets ORF2.

[0026] All other aspects of the dsRNA targeting pathogens other than EHP are as discussed above with respect to the dsRNA targeting EHP. Thus, for instance, the dsRNA can target any region of the mRNA of a gene essential to the life cycle of the pathogen (e.g., genes essential for the viral life cycle or parasite life cycle). Furthermore, the dsRNA may be of any suitable length, and can be a hairpin construct (hairpin-dsRNA) or non-hairpin construct. The dsRNA typically have a length of 50 bp or more (e.g., 75 bp or more, or 100 bp or more). In some instances even longer dsRNA are desired, such as 125 bp or more, 150 bp or more, or even 200 bp or more. In some embodiments, the dsRNA will have no more than 1000 bp, such as 750 bp or less, or 500 bp or less (e.g., 300 bp or less or 250 bp or less). Any of the foregoing lower and upper limits ondsRNA lengths can be set out as ranges (e.g., 50-1000 bp, 50-750 bp, 50-500 bp, 50-300 bp, 50- 250, 75-1000 bp, 75-750 bp, 75-500 bp, 75-300 bp, 75-250, 100-1000 bp, 100-750 bp, 100-500 bp, 100-300 bp, 100-250, 1250-1000 bp, 125-750 bp, 125-500 bp, 125-300 bp, 125-250, 150- 1000 bp, 150-750 bp, 150-500 bp, 150-300 bp, 150-250 200-1000 bp, 200-750 bp, 200-500 bp, 200-300 bp, 200-250, etc.). In some embodiments, the dsRNA has a length of 100-500 bp (e.g. 100-400 bp, 100-300 bp, or 100-250 bp), or 150-500 bp (e.g., 150-400 bp, 150-300 bp, or 150- 250 bp). The foregoing dsRNA lengths refer to the double stranded portion of the dsRNA molecule (e.g., the portion of the dsRNA that hybridizes to a target mRNA, not including any hairpin loop region that might be present).

[0027] The microalgae can be engineered to express the dsRNA by introducing into the microalgae a nucleic acid that encodes the dsRNA. Thus, the engineered microalgae provided herein also can be described has comprising a nucleic acid sequence, or nucleic acid molecule, encoding the dsRNA that targets the pathogen as described herein. The nucleic acid can be introduced as an expression construct that remains independent of the microalgae genome, or as an expression construct that integrates into the microalgae genome.

[0028] Transformation of the microalgae with the expression vector can be done by any suitable technique in the art, including, e.g., biolistics, electroporation, glass bead transformation silicon carbide whisker transformation, use of a laser beam, microinjection or any other method capable of introducing DNA into a microalgae. See Maruyama et al., Introduction of foreign DNA into Chlor lla saccarophila by electroporation Biotechnology Techniques 2004, 8:821- 826). Recombinant DNA can also be introduced into microalgae by forming protoplasts and using CaCh and polyethylene glycol (PEG). See Kim et al., 2002, Mar. Biotechnol. 4:63-13,' Sanford, Trends In Biotech. (1988) 6:299-302, U.S. Patent No. 4,945,050; Fromm et al., Proc. Nat'l. Acad. Sci. (USA) (1985) 52:5824 5828).

[0029] Engineered microalgae can also be prepared using homologous recombination, which utilizes complementary DNA sequences to align and exchange regions of homology. In homologous recombination, after transgenic “donor” DNA containing a sequence that is homologous to the target genomic sequence (the “template”) is introduced into the organism, the donor and target sequences align and undergo recombination into the genome at the site of the corresponding target sequence. Generally, homologous recombination can be described by thefollowing stepwise process: (1) the homologous donor and target DNA segments align; (2) host enzymes introduce one or more double-stranded breaks into the donor DNA molecule; (3) the template DNA molecule is invaded by the ends of the free donor DNA forming a crossover or Holliday junction; (4) DNA synthesis occurs and “branch migration” extends the heteroduplex region away from the site of crossover, and completes the broken strands; and (5) double-strand break repair by host machinery yield the final recombination products. The end result, in a designed homologous recombination process, is the integration of a target sequence into the host genome.

[0030] The use of designed homologous recombination in a host organism such as a microalgae has many practical implications for what can be carried out at the molecular genetic level and is useful in the generation of microalgae to express a desired transcript or protein product. Homologous recombination is precise and results in insertion of the target sequence directly into the microalgal host chromosome, thus the genetic stability is high relative to other methods like the introduction of plasmid DNA. This precision allows homologous recombination to be used to modify specific nucleotides, provided flanking regions are identified. Homologous recombination can also be used to exploit specific host regulatory elements, such as endogenous promoters, to drive heterologous gene expression in a specific, desired manner.

[0031] Targeting constructs can be transformed into the host cell in any suitable form known in the art, for example, as a supercoiled plasmid DNA with a vector backbone, as a PCR product with no vector backbone, or as a linear molecule. The donor DNA may, prior to transformation, be treated with one or more restriction enzymes to increase the efficiency of recombination. PCR may also be used to generate donor DNA containing linear ends homologous to the target genomic sequences. Constructs containing pieces of host sequences are designed to "target" the gene or region of interest within the endogenous host cell genome. These targeting sequences can be positioned such that they are 5' with respect to the target gene or region of interest, 3' with respect to the target gene / region of interest or flanking the target gene / region of interest.

[0032] Vectors that may be used for the transformation of microalgae in accordance with the present disclosure may be any suitable vector known in the art and can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein. Such vectors typically contain one or more nucleic acid sequences that encode a desired product (the geneproduct), which are operably linked to one or more gene control sequences (for example, a promoter sequence) that regulate expression or facilitate targeting of the gene product to a particular location in the recombinant cell.

[0033] The term “gene control sequences” refers to any nucleic acid sequence that regulates the expression of a gene coding sequence or that plays a role in the localization of a gene product. Gene control sequences may include, for example, promoters that regulate transcription of a coding sequence and terminators that terminate transcription of a coding sequence. Another example of a gene control sequence is a 3' untranslated sequence located at the end of a coding sequence that encodes a polyadenylation signal. Gene control sequences that contribute to the localization of gene products include those that encode signal peptides.

[0034] Vectors suitable for use in the present disclosure may include either endogenous promoters or exogenous promoter sequences that are functional in microalgae, such as promoter sequences that are active in the microalgae being used (e.g., promotors useful in Prototheca). Many promoters are active in microalgae and suitable for use in vectors for transformation. Such promoters include, for example, Chlamydomonas reinhardtii P-tublin promoter, Chlorella sorokiniana glutamate dehydrogenase promoter / 5 'UTR, Chlorella HUP1 gene promoter, Chlorella ellipsoidea nitrate reductase promoter, Prototheca promoter S AD2, or Prototheca promoter FATA, or functional portions thereof.

[0035] Alternatively, the vector might not include a promoter in operable linkage with a gene of interest, but may be designed such that the gene of interest is transformed into cells such that it becomes operably linked with an endogenous promoter, e.g., by targeted homologous recombination. The use of transformation vectors without promoters has been demonstrated to work in microalgae. See, e.g., Lubreras, V. et al., Plant Journal 14:4, 1998, pp.441-447.

[0036] The promoter sequence may be inducible or constitutively active. Constitutive promoters drive expression at all times (or at certain times in the cell life cycle) at the same level. Inducible promoters, conversely, are active (or become inactive) or are up- or down-regulated only in response to a stimulus. Both constitutive and inducible promoters are useful in embodiments of the present disclosure. Inducible promoters include those that mediate transcription of an operably linked gene in response to a stimulus, such as an exogenously provided small molecule, temperature (heat or cold), lack of nitrogen in culture media, etc.Suitable promoters can activate transcription of an essentially silent gene or upregulate, preferably substantially, transcription of an operably linked gene that is transcribed at a low level.

[0037] The vector optionally includes termination region gene control sequences. Such termination regions may be of any type or sequence known in the art suitable for the particular purpose intended.

[0038] In some embodiments, the engineered microalgae comprises one or more vectors encoding a dsRNA described herein. The vector may be a nucleic acid vector of any type known in the art. In some embodiments, the vector may include a promoter sequence that is active in the microalgae (e.g., Prototheca), such as a Chlamydomonas reinhardtii -tublin promoter, Chlor ella sorokiniana glutamate dehydrogenase promoter / 5 'UTR, Chlorella HUP1 gene promoter, Chlorella ellipsoidea nitrate reductase promoter, Prototheca promoter SAD2, or Prototheca promoter FATA.

[0039] When the engineered microalgae is an achlorophyllous algae, such as Prototheca, the microalgae can be grown using heterotrophic cultivation without light and with the controlled addition of an organic source of carbon and energy in a conventional bioreactor. Techniques for such cultivation are known in the art (e.g., Bumbak et al., Appl Microbiol Biotechnol. 2011; 91(1) 31-46).

[0040] The engineered microalgae can be used as a whole-cell preparation, with or without lysis. In some embodiments, the engineered microalgae is lysed prior to use. Whether lysed or not lysed, the engineered microalgae can be dried prior to use. The lysis and / or drying process may be accomplished by any method known in the art, such as, for example, by drum drying, vacuum drum drying, rotary vacuum drying, freeze drying, spray drying, or high atomization drying. For example, the moisture content of a lysed and / or dried microalgae may be 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, or 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less. The moisture content of some embodiments may fall within any ranges or have any values; for example, between 0.5 - 10%, 0.5- 9%, 0.5-8%, 0.5-7%, 0.5-6%, 0.5-5%, 0.5-4%, 0.5-3%, 0.5-2%, 0.5-1%, or 0.5-0%. In any embodiment, the moisture content of the lysed and / or dried microalgae may be measured or ascertained according to any suitable method known in the art.

[0041] In some embodiments, the lysed and / or dried microalgae can be processed to have a desired particle size distribution. The particle size may be achieved by any method known in the art, for example, by milling, or may be achieved as part of the lysing and / or drying process, for example, by high atomization drying.

[0042] In some embodiments, 90% or more of the total volume (Dv90) of dried microalgae may have a particle size of 600 microns or less. For instance, the lysed and / or dried microalgae may have a particle size distribution (Dv90) of about 550 microns or less, about 500 microns or less, about 450 microns or less, or about 400 microns or less. In some embodiments, the particles size distribution (Dv90) of the lysed and / or dried microalgae may be about 400-600 microns, or any value or range in-between.

[0043] In some embodiments, 90% or more of the total volume (Dv90) of dried microalgae may have a particle size of 100 microns or less. For instance, the lysed and / or dried microalgae may have a particle size distribution (Dv90) of about 100 microns or less, about 95 microns or less, about 90 microns or less, about 85 microns or less, about 80 microns or less, about 75 microns or less, about 70 microns or less, about 65 microns or less, about 60 microns or less, about 55 microns or less, about 50 microns or less, about 45 microns or less, about 40 microns or less, about 35 microns or less, about 30 microns or less, about 25 microns or less, about 20 microns or less, about 15 microns or less, about 10 microns or less, or about 5 microns or less. In some embodiments, the particles size distribution (Dv90) of the lysed and / or dried microalgae may be about 5 to 100 microns, or any value or range in-between. In some embodiments, the particle size distribution (Dv90) of the lysed and / or dried microalgae may be 5-75 microns, 10- 75 microns, 15-75 microns, 20-75 microns, 25-75 microns, 30-75 microns, 35-75 microns, 40-75 microns, 45-75 microns, 50-75 microns, 55-75 microns, 60-75 microns, 65-75 microns, or 70-75 microns.

[0044] The engineered microalgae described herein can be part of a composition comprising a dispersant, such as an oil (e.g., fish oil or triglyceride oil), which can be used as a feed additive. In some embodiments, the composition comprises a dispersant and 0.1 wt.% or more (e.g., 0.1 wt.% or more, 1 wt.% or more, 5 wt.% or more, 10 wt. % or more 15 wt.% or more or even 20 wt.% or more ) dried microalgae. In some embodiments, the amount of microalgae will be 30 wt.% or less (e.g., 0.1-30 wt.%, 1-30 wt.%, 5-30 wt.%, 10-30 wt.%, 15-30 wt.%, or 20-30 wt.%).In other embodiments, the loading level of the microalgae can 30 wt.% or more (such as 40 wt.% or more 50 wt.% or more, 60 wt.% or more, 70 wt.% or more, or even 80 wt.% or more). For instance, the amount of microalgae can be in the range of 30-90 wt.%, 30-80 wt.%, 30-70 wt.%, 30-60 wt.%, 30-50 wt.%, 40-90 wt.%, 40-80 wt.%, 40-70 wt.%, 40-60 wt.%, or 40-50 wt.%.

[0045] The aquaculture feed additive can be prepared by any suitable method. In some embodiments, the method comprises lysing or drying an engineered microalgae cells, wherein sufficient oil is released from the cells to provide the dispersion media. In other embodiments, a dispersion media is combined with the lysed and / or dried microalgae.

[0046] Also provided herein is an aquaculture feed pellet comprising an engineered microalgae, which can be dried or lysed as described above. In addition to the engineered, the feed pellets generally contain an organic substrate in substantially solid pelleted form suitable for feeding to crustaceans in aquaculture. In some embodiments, the feed pellet includes one or more ingredients such as but not limited to, for example, fish meal, middling such as wheat middling, flour such as wheat flour, wheat gluten, blood meal, oyster shell, cellulose, alcohol powder, oils such as fish oil, triglyceride oils, and / or allicin, soybean phosphatides, lecithin (such as soy lecithin, calcium lactate, soymeal, peanut meal, peanut cake, shrimp powder, mineral premixes, starch (such as potato starch) choline chloride, vitamins, mineral elements, and amino acids. In some embodiments, the feed pellet may further include a dispersion media. The dispersion media may be any suitable dispersion media known in the art that is suitable for use in aquaculture. In some embodiments, the dispersion media is an oil, such as a fish oil or triglyceride oil.

[0047] The engineered microalgae can be integrated into the pellet (e.g., integrated during pellet fabrication) or can be on the surface of the pellet as a coating. In some embodiments, the feed pellet comprises at least 0.1 wt.% (0.5 wt.% or more, 1 wt.% or more, 2 wt.% or more, 3 wt.% or more, or 4 wt.% or more) of the dried engineered microalgae based on the dry weight of the feed pellet. The feed pellet typically will comprise 30 wt.% or less of the dried engineered microalgae. For example, the feed pellet can comprise 0.1 to 10 wt.%, 0.1 to 7 wt.%, or 0.1 to 5 wt.% (e.g., 0.5-5 wt.%, 1-5 wt.%, 2-5 wt.%, or 3-5 wt.%) of the dried engineered microalgae.

[0048] The feed pellets comprising the engineered microalgae can be prepared by any suitable method. For instance, the method can comprise combining or mixing the engineeredmicroalgae (optionally lysed or dried, optionally in a dispersant, as described herein) or aquaculture feed additive comprising the engineered microalgae as described herein, with the other components of the feed pellet to provide a feed mixture, and pelleting the mixture to provide aquaculture feed pellets. Pelleting can be performed according to any method known in the art, for example, using a pellet mill, extrusion, or other suitable technique.

[0049] In other embodiments, an aquaculture feed additive comprising the engineered microalgae and a dispersant as described herein is applied to the surface of previously prepared aquaculture feed pellets. The feed additive can be applied to the feed pellets by any suitable technique, such as by spraying.

[0050] Also provided herein is a method of inhibiting or treating a pathogenic EHP infection in a crustacean. Inhibiting or treating an infection encompasses any reduction of the severity or progress of infection or any symptom thereof in a host, in any manner and to any degree. Inhibition or treatment can be by any mode of action, such as by interfering with the reproduction or spread of the pathogen in the host. In some embodiments, the method prevents the infection from progressing to a clinical disease state. In some embodiments, the method reduces the severity of a clinical disease state and / or prevents reduced growth rate, stunting, and / or death from the infection.

[0051] In some embodiments, these methods comprise administering to the crustacean engineered microalgae as described herein, such as by supplying the engineered microalgae to the crustacean in aquaculture media (e g., the medium in which the crustacean is farmed, typically seawater and nutrients), whereby the crustacean ingests the microalgae. In some embodiments, the engineered microalgae can be administered as a part of a composition, such as aquaculture feed pellet or an aquaculture feed additive as described herein. The administration can be to a crustacean already infected with the pathogen, or to a crustacean before the crustacean is infected with the pathogen, such that the infection will be inhibited or treated once it occurs.

[0052] The crustacean of the method may be any crustacean known the art and used in aquaculture that is susceptible to the pathogen targeted by the dsRNA of the engineered microalgae. In some embodiments, the crustacean is a shrimp. The shrimp may be any species of shrimp, for example, the shrimp may be Akikami past shrimp, Baltic prawn, Banana prawn,Blue Shrimp, Brine shrimp, Brine Shrimp Brown tiger prawn, Caramote prawn, Eastern King prawn, Eastern School Shrimp, Fleshy prawns, Freshwater prawn, shrimp giant river prawn, giant tiger prawn, greasy back shrimp, green tiger prawn, Indian white prawn, Karuma prawn, Metapenaeus shrimp, Northern White Shrimp, Karuma prawn, Palaemonid shrimp, Redtail prawn, Southern White Shrimp, Pacific White Shrimp, Atlantic White Shrimp, or Whiteleg Shrimp.

[0053] All other aspects of the method of treating or preventing a pathogenic infection in a crustacean are as described with respect to the engineered microalgae, and feed additive and feed pellets comprising same.

[0054] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0055] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. Nolanguage in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0056] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims

CLAIM(S):

1. An engineered microalgae comprising a double stranded RNA (dsRNA) that targets Enterocytozoon hepatopenaei.

2. The engineered microalgae of claim 1, wherein the dsRNA comprises a sequence complementary to an mRNA encoding an Enterocytozoon hepatopenaei polar tube protein, spore wall protein, nucleoside transport protein, glucose-6-phosphate dehydrogenase, methionine aminopeptidase, micorosomal signal peptidase, or hexokinase.

3. The engineered microalgae of claim 1, wherein the dsRNA comprises a sequence complementary to an mRNA encoding an Enterocytozoon hepatopenaei Polar Tube Protein.

4. The engineered microalgae of claim 1, wherein the dsRNA comprises a sequence complementary to an mRNA encoding an Enterocytozoon hepatopenaei HXK, NTT-1, SWP, SWP-1, SWP-7, SWP- 12, ZWF1 , MAP2, or SPCS1.

5. The engineered microalgae of claim 1, wherein the dsRNA comprises a sequence complementary to an mRNA encoding an Enterocytozoon hepatopenaei ATP / ADP transporter protein, optionally ATP-ADP Carrier Protein, ADP-ATP Carrier Protein, or ADP-ATP Carrier Protein 4.

6. The engineered microalgae of claim 1, wherein the dsRNA comprises a sequence complementary to an mRNA encoding an Enterocytozoon hepatopenaei mitosomal protein.

7. The engineered microalgae of any of claims 1-6, wherein the dsRNA comprises 50-5000 bp, optionally 500-1500 bp.

8. The engineered microalgae of any of claims 1-7, wherein the microalgae is a Prototheca microalgae.

9. The engineered microalgae of claim 8, wherein the microalgae is a non- pathogenic species of Prototheca, optionally Prototheca morifornris or Prototheca zopfii (GT1).Leydig 5148412210. The engineered microalgae of any of claims 1-9, further comprising a vector, wherein the vector comprises(a) a promoter that is active in the engineered microalgae, and(b) a nucleic acid sequence operably linked to the promoter that encodes the double stranded RNA (dsRNA).

11. The engineered microalgae of claim 10, wherein the promoter is a Chlamydomonas reinhardtii 0-tublin promoter, Chlorella sorokiniana glutamate dehydrogenase promoter / 5 'UTR, Chlorella HUP 1 gene promoter, or Chlorella ellipsoidea nitrate reductase promoter.

12. The engineered microalgae of claim 10, wherein the promoter is an inducible promoter.

13. The engineered microalgae of any of claim 10, wherein the promoter is a constitutively active promoter.

14. The engineered microalgae of any of claims 1-13, wherein the microalgae is lysed and / or dried to a moisture content of 10% or less, optionally 6% or less, or 0.5-6% .

15. The engineered microalgae of any of claims 1-14, wherein the microalgae is a dried microalgae with a particle size distribution in which 90% or more of the total volume (Dv90) of the dried microalgae has a particle size of 75 microns or less, optionally 25-75 microns; or wherein the microalgae is a dried microalgae with a particle size distribution in which 90% of the total volume (Dv90) of the dried microalgae has a particle size of 400-600 microns.

16. Aquaculture feed pellet comprising the engineered microalgae of any of claims 1- 15.

17. The aquaculture feed pellet of claim 16, wherein the feed pellet comprises 0.1-30 wt.%, optionally 0.1 to 5.0 wt.% of the engineered microalgae.Leydig 5148412318. An aquaculture feed additive comprising the engineered microalgae of any of claims 1-15 and a dispersion media.

19. The aquaculture feed additive of claim 18, wherein the dispersion media comprises an oil.

20. The aquaculture feed additive of claim 18, wherein the dispersion media comprises a fish oil or triglyceride oil.

21. The aquaculture feed additive of any of claims 18-20, wherein the feed additive comprises 0.1 to 30.0 wt.% of the engineered microalgae.

22. A method of preparing an aquaculture feed additive of any of claims 18-21, the method comprising drying the engineered microalgae, wherein the method further comprises either lysing the cells to release sufficient oil to provide a dispersion media, or combining the dried microalgae with a dispersion media.

23. The method of claim 22, wherein the engineered microalgae is dried by drum drying, vacuum drum drying, rotary vacuum drying, freeze drying, or spray drying, optionally with milling to reduce the particle size of the dried microalgae.

24. The method of claim 22, wherein the engineered microalgae is dried by high atomization drying to provide dried microalgae with a Dv90 particle size distribution of 75 microns or less, optionally 25-75 microns.

25. A method of preparing an aquaculture feed pellet according to claim 16 or 17, the method comprising(a) combining the aquaculture feed additive of any of claims 18-21 with aquaculture feed pellet ingredients to provide a feed mixture, and pelletizing the feed mixture; or(b) applying the aquaculture feed additive to aquaculture feed pellets.

26. The method of claim 25, wherein the aquaculture feed additive is provided according to the method of any of claims 22-24.Leydig 5148412427. A method of inhibiting a pathogenic Enterocytozoon hepatopenaei viral infection in a crustacean, the method comprising administering to the crustacean engineered microalgae of any of claims 1-15, the feed pellet of any of claims 16-17, or the feed additive of any of claims 18-21.

28. The method of claim 27, wherein the engineered microalgae is administered to the crustacean by supplying the microalgae to aquaculture media.

29. The method of claim 27 or 28, wherein the crustacean is a shrimp.

30. The method of claim 29, wherein the shrimp is Akikami past shrimp, Baltic prawn, Banana prawn, Blue Shrimp, Brine shrimp, Brine Shrimp Brown tiger prawn, Caramote prawn, Eastern King prawn, Eastern School Shrimp, Fleshy prawns, Freshwater prawn, shrimp giant river prawn, giant tiger prawn, greasy back shrimp, green tiger prawn, Indian white prawn, Karuma prawn, Metapenaeus shrimp, Northern White Shrimp, Karuma prawn, Palaemonid shrimp, Redtail prawn, Southern White Shrimp, Pacific White Shrimp, Atlantic White Shrimp, or Whiteleg Shrimp.

31. The engineered microalgae of claim 1 , wherein the microalgae is a Prototheca microalgae.

Citation Information

Cited By

  • Epinephelus enterospora spore wall protein SWP26 as well as preparation and application of polyclonal antibody of grouper enterospora enterospora spore wall protein SWP26

    CN121108277A